Given that MYC is a downstream target of IGF2BP2 and a crucial regulator of glycolysis, further investigations revealed that E6/E7 can modulate aerobic glycolysis in cervical cancer cells through the m6A‐MYC pathway mediated by IGF2BP2 both in vitro and in vivo. Here, MYC is linked to cervical cancer.